Rigel Pharmaceuticals (RIGL) Interest Coverage Ratio (2010 - 2026)
Rigel Pharmaceuticals' quarterly Interest Coverage Ratio came in at 8.29 in Q1 2026, up 20.32% year-on-year from 6.89 in Q1 2025, and down 39.18% quarter-over-quarter from 13.64 in Q4 2025.
Rigel Pharmaceuticals has reported Interest Coverage Ratio for 10 years, with the latest figure at 8.29 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 20.32% year-over-year to 8.29; the trailing twelve-month figure through Mar 2026 stood at 18.05 (up 224.55% YoY), and the FY2025 full-year result was 17.14, up 460.99% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 8.29, down from 13.64 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 32.61 in Q2 2025, with the low at 22.79 in Q2 2022.
- Average Interest Coverage Ratio over 5 years is 0.5, with a median of 1.03 recorded in 2023.
- Year-over-year, Interest Coverage Ratio tumbled 207.17% in 2022 and jumped 14700.2% in 2025.
- Tracing RIGL's Interest Coverage Ratio over 5 years: stood at 1.88 in 2022, then sank by 45.11% to 1.03 in 2023, then surged by 726.35% to 8.52 in 2024, then surged by 60.08% to 13.64 in 2025, then plunged by 39.18% to 8.29 in 2026.
- The last three Interest Coverage Ratio figures came in at 8.29 (Q1 2026), 13.64 (Q4 2025), and 15.01 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 8.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.29 |
| Dec 31, 2025 | 13.64 |
| Sep 30, 2025 | 15.01 |
| Jun 30, 2025 | 32.61 |
| Mar 31, 2025 | 6.89 |
| Dec 31, 2024 | 8.52 |
| Sep 30, 2024 | 6.82 |
| Jun 30, 2024 | 0.22 |
| Mar 31, 2024 | -3.72 |
| Dec 31, 2023 | 1.03 |
| Sep 30, 2023 | -2.35 |
| Jun 30, 2023 | -2.83 |
| Mar 31, 2023 | -10.57 |
| Dec 31, 2022 | 1.88 |
| Sep 30, 2022 | -22.28 |
| Jun 30, 2022 | -22.79 |
| Mar 31, 2022 | -21.79 |
| Dec 31, 2021 | -16.49 |
| Sep 30, 2021 | -15.02 |
| Jun 30, 2021 | -7.42 |
| Mar 31, 2021 | 86.09 |
| Dec 31, 2020 | -43.89 |
| Sep 30, 2020 | -32.12 |
| Jun 30, 2020 | -49.27 |
| Mar 31, 2020 | 148.08 |
| Dec 31, 2019 | -53.02 |
| Sep 30, 2019 | -1,504.63 |
| Dec 31, 2011 | -8,636.67 |
| Sep 30, 2011 | -4,510.25 |
| Jun 30, 2011 | -3,079.57 |
| Mar 31, 2011 | -1,896.36 |
| Dec 31, 2010 | -936.62 |
| Sep 30, 2010 | 3,357.20 |
| Jun 30, 2010 | 1,079.12 |